|
|
 |
|
Viewing report
|
|
|
|
Gastric Cancer - Targeted Therapies Compete for First-to-Market Status
Datamonitor, April 2009, Pages: 76
Gastric cancer incidence in 2009 is forecast to be 197,000 in the seven major pharmaceutical markets (US, Japan, Germany, France, Italy, Spain, and UK). Although, the global incidence has decreased in recent years, mortality remains high, particularly in the US and Europe. Therefore, predictably a high unmet need remains for effective therapies to improve mortality.
Scope
- Gastric cancer overview, including definition, risk factors, epidemiology forecasts and discussion of unmet needs
- Current diagnosis and treatment of gastric cancer, including drug regimens used by stage and ongoing controversies
- Examination of the late-phase gastric cancer pipeline and market opportunities for drug developers
- Stakeholder opinions based on qualitative interviews with key opinion leaders in the field of gastric cancer
Highlights of this title
Surgery is the mainstay of gastric cancer treatment. Chemotherapyalone or in combination with radiotherapyhas a role in the treatment of both early-stage and locoregional disease. However, its main application is in the treatment of advanced disease, where it is used with palliative intent and only results in a poor median survival of 79 months.
The Phase III gastric cancer pipeline comprises six drugs, five of which are molecular targeted therapies. All the drugs in the pipeline are intended for use in the first-line treatment of advanced gastric cancer.
The gastric cancer market is currently attracting R&D interest from key pharmaceutical players. Drugs such as Avastin (bevacizumab; Genentech/Roche/Chugai), Herceptin (trastuzumab; Genentech/Roche/Chugai), and Tykerb (lapatinib; GlaxoSmithKline) are seeking line extensions. Approval of any agents will result in a very competitive market.
Key reasons to purchase this title
- To estimate the number of treatable patients and understand where high unmet needs exist which may provide opportunity for pipeline agents
- To gain insight into the current dynamics of gastric cancer management
- To analyze the current gastric cancer pipeline drugs and understand effects of approval on market dynamics
Customers who bought this item also bought
Gastric Cancer - Targeted Therapies Home In On a Neglected Tumor Type
Niche Cancers 2001: Gastric Cancer
Pipeline Insight: Cancer Overview - Gastrointestinal, Skin, Sarcomas
Digestive System - Peptic Ulcer or Gastric Ulcer or Duodenal Ulcer Drug Pipeline Report
Gastric Cancer: Looking to the East for Inspiration?
Digestive System Peptic Ulcer or Gastric Ulcer or Duodenal Ulcer
Gastric Cancer Overview - Raising the Standard: Japanese Inspiration and a New Era of Giants
Peptic Ulcer or Gastric Ulcer or Duodenal Ulcer Therapy Area Pipeline Report
Pipeline Insight: Breast Cancer - Recent Approvals Increase Pressure On Pipeline Candidates
Stakeholder Opinions: Esophageal Cancer Treatment Paradigms Need Revolution Not Evolution
Cancer Drug Discoveries: What the Future Holds: Prostate Cancer Chapter
Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor types
|
|
|
|
